Anonymous cancer metastases in the long bones of the limbs: approaches to the screening and treatment

E.A. Solonitsyn, F.V. Klimovitskiy, V.V. Protsenko

Abstract


The article reports the results of examination and treatment of 50 patients with anonymous cancer metastases in bones. Patients underwent a comprehensive examination: X-ray of the lesion in the bone; X-ray and computed tomography of the chest cavity; ultrasound, computed tomography or magnetic resonance imaging of abdominal organs, retroperitoneal space and pelvis; bone scan; computed tomography or magnetic resonance imaging of the brain; positron emission tomography. To verify the process, an open or punch biopsy of metastatic lesions in bone was performed. Histogenesis of the tumor was determined as follows: in 29 (58 %) patients — glandular cancer, in 15 (30 %) — squamous cell carcinoma, in 6 (12 %) — high-grade cancer. Medical tactic was determined by taking into account the patient’s general condition, localization of metastases, incidence of tumor, metastatic tumor morphological structure, the supposed localization of the primary tumor. In 41 patients with multiple metastases, in cases of severe general condition of the patient and the refusal of the surgery, there was carried out plaster cast immobilization of the limb affected by metastases. Six patients with a relatively satisfactory general state underwent organ-preserving surgeries. In 3 patients, we have performed mutilating surgeries (amputation and disarticulation of the limb). After the diagnostic, conservative and surgical measures, all patients continued comprehensive (chemotherapy, radiation therapy, bisphosphonates) or symptomatic treatment. The chemotherapy regimens in patients with anonymous cancer metastases were chosen according to histological type of tumor. All patients were treated with bisphosphonates (zolendronic acid, pamifos, pamiredin) at intervals of 28 days, from 6 to 10 courses. Radiation therapy was administered to the lesion in the bone in cases of severe pain syndrome and the threat of appearance or presence of pathological fracture to a total focal dose of 40–60 Gray. In the future, patients with anonymous cancer metastases in bones of the skeleton continued examination in order to detect primary malignant tumor.
As a result of the treatment, it was found that the life expectancy of patients with anonymous cancer metastases, who received comprehensive treatment, is higher than in patients, whose treatment was limited to symptomatic therapy.


Keywords


anonymous cancer metastases; metastatic bone disease; examination; treatment

References


Комаров И.Г., Комов Д.В. Метастазы злокачественных опухолей без выявленного первичного очага. — М.: Триада-Х, 2002. — 136 с.

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin / J.L. Abbruzzese, M.C. Abbruz-

zese, R. Lenzi et al. // J. Clin. Oncol. — 1995. — Vol. 13. — P. 2094-2103.

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide / J.D. Hainsworth, J.B. Erland, L.A. Kalman et al. // J. Clin. Oncol. — 1997. — Vol. 15. — Р. 2385-2393.

Cervical lymph node metastases from unknown primary tumors / C. Grau, L.V. Johansen, J. Jakobsen et al. // Radiother. Oncol. — 2000. — Vol. 55. — P. 121-129.

Combined modality therapy with chemoradiation for squamous cell carcinoma of the head and neck from an occult primary / S.M. Smith, A. Argiris, K. Stenson et al. // Proc. Am. Soc. Clin. Oncol. — 2002. — Vol. 21. — Р. 235.

Diagnostic and therapeutic management of cancer of unknown primary / N. Pavlidis, E. Briasoulis, J. Hainsworth et al. // Eur. J. Cancer. — 2003. — Vol. 39. — Р. 1990-

Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study / F.A. Greco, H.A. Burris, S. Lit-chy et al. // J. Clin. Oncol. — 2002. — Vol. 20. —

Р. 1651-1656.

Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site / D. Pouessel, S. Culine, C. Becht et al. // Cancer. — 2004. — Vol. 100. — Р. 1257-1261.

Hainsworth J.D. Carcinoma of unknown primary site / J.D. Hainsworth // Cancer Management: A Multidisciplinary Approach. Medical, Surgical & Radiation Onco-logy. Pazdur R., Coia L.R., Hoskins W.J., Wagman L.D. (eds.). — New York: Masson, 2002. — P. 947-978.

Hainsworth J.D. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience / J.D. Hainsworth, D.H. Johnson, F.A. Greco // J. Clin. Oncol. — 1992. — Vol. 10. — Р. 912-922.

Hainsworth J.D. Treatment of patients with cancer of an unknown primary site / J.D. Hainsworth, F.A. Greco // N. Engl. J. Med. — 1993. — Vol. 329. — Р. 257-263.

Schapira D.V. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma / D.V. Schapira, A.R. Jarrett // Arch. Intern. Med. — 1995. — Vol. 155. — Р. 2050-2054.

Taxane-based chemotherapy for patients with carcinoma of unknown primary site / F.A. Greco, J. Gray, H.A. Burris

et al. // Cancer J. — 2001. — Vol. 7. — Р. 203-212.

Treatment of metastatic poorly differentiated neuroendocrine carcinoma with paclitaxel/carboplatin/etoposide: A Minnie Pearl Cancer Research Network phase II trial / C.E. McKay,

J.D. Hainsworth, H.A. Burris et al. // Proc. Am. Soc. Clin.

Oncol. — 2002. — Vol. 21. — Р. 158.




DOI: https://doi.org/10.22141/1608-1706.1.18.2017.95597

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 TRAUMA

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru